Evolva and Breko GmbH, Bremen, Germany have signed an agreement for the exclusive distribution of Evolva?s Veri-teTM Resveratrol for use in dietary supplements covering Germany, Austria, Thailand and Vietnam. The partners have already been working together for more than five years, resulting in compound annual revenue growth of more than 50%. With this agreement on an exclusive basis, this very successful relationship is now being formalized.

The agreement underscores the potential of Veri-teTM Resveratrol as a powerful and sustainable high-quality ingredient for use in dietary supplements as well as for use in foods in select countries. The agreement broadens the already existing long-term partnership by granting exclusivity to Breko and covering additional markets. Breko was already instrumental in obtaining approval for Veri-teTM Resveratrol from the Thai Food and Drug Administration earlier this year.

Veri-teTM Resveratrol is the main pillar of Evolva?s Health Ingredients (HI) business and was a key driver for the 14% revenue growth in HI recorded in the first half of 2023.